First Trust Advisors LP Cuts Stake in Maravai LifeSciences Holdings, by 10.0%
June 6, 2023
☀️Trending News
First Trust Advisors LP, a renowned institutional investor, recently decreased its ownership in Maravai ($NASDAQ:MRVI) LifeSciences Holdings, Inc. by 10.0%. Maravai LifeSciences is a life sciences technology company that offers complete supply chain solutions and services to the healthcare, biopharmaceutical, and research markets. It provides services such as manufacturing, packaging, distribution, research and product development, and supply chain management. The company also offers laboratory automation services and sequencing services. Maravai LifeSciences’ mission is to help life science organizations create a more efficient and reliable supply chain that meets the needs of their customers.
It uses advanced technologies to create value and build trust with its customers and partners. The company has developed innovative ways to streamline the manufacturing process and ensure quality products are delivered in a timely manner. It also provides data collection and analytics services to help its customers make informed decisions.
Analysis
At GoodWhale, we recently performed an analysis on MARAVAI LIFESCIENCES‘s wellbeing. After our review, we have concluded that MARAVAI LIFESCIENCES is a medium risk investment based on our Risk Rating. We have identified three risk warnings in the income sheet, balance sheet, and cashflow statement that potential investors should consider before investing. To view the specifics of these risk warnings, become a registered user with GoodWhale. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 717.73 | 153.28 | 21.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
| Operations | Investing | Financing |
| 458.75 | -95.76 | -166.19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.32k | 1.41k | 3.96 |
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 83.4% | 185.6% | 57.1% |
| FCF Margin | ROE | ROA |
| 60.8% | 48.0% | 11.1% |
Peers
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
Summary
Investors appear to be optimistic about Maravai LifeSciences Holdings, Inc., with stock prices rising the same day that First Trust Advisors LP, a major institutional investor, lowered its stake in the company by 10.0%. This indicates that investors are still confident in Maravai’s potential despite the reduction in holdings. Analysts are watching to see if other large fund managers follow suit, as it may provide an indication of the current sentiment towards the stock. The stock could be a good buy for long-term investors looking for a stable investment opportunity.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
